HIROTSU BIO SCIENCE employs the world’s
state-of-the-art nematode behavior analysis technology and
clinical research results in order to pursue
effective and affordable early detection of cancer

PRESS
RELEASE

• 2018.08.06
  HIROTSU BIO SCIENCE raised capital of 1.4 billion yen by allocation of new stocks to third parties
• 2018.06.27
  General incorporated association “Empower Children” and limited liability company “AVEX & HIROTSU BIO EMPOWER LCC.” are established to help pediatric cancer patients
• 2018.02.05
  HOUKEN CORP. & HIROTSU BIO SCIENCE INC.. are in the tie-up.
• 2018.02.02
  A research project aiming to develop the worldwide “N-NOSE” nematode cancer test started.
• 2017.10.26
  Shinkin Bank fund “Shinkin no Tsubasa” has announced that it will support the global expansion of HIROTSU BIO SCIENCE INC., toward the “practical application of cancer test using nematodes”.